Research Horizons


In NEJM: Dose Escalation Best Approach for Sickle Cell Med in Africa

“The study shows clearly that the optimized dosing strategy for hydroxyurea, though it requires more effort than a fixed-dose treatment regimen, results in far better outcomes for children with sickle cell anemia,”

— Russell Ware, MD, PhD

Read the media release about the NOHARM MTD study

Publication Information
Original title: Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa
Published in: New England Journal of Medicine
Publish date: June 25, 2020
Read the Study